Health & Environmental Research Online (HERO)


Print Feedback Export to File
7139518 
Journal Article 
TOPGEAR: a randomised phase III trial of perioperative ECF chemotherapy versus preoperative chemoradiation plus perioperative ECF chemotherapy for resectable gastric cancer (an international, intergroup trial of the AGITG/TROG/EORTC/NCIC CTG) 
Leong, T; Smithers, BM; Michael, M; Gebski, V; Boussioutas, A; Miller, D; Simes, J; Zalcberg, J; Haustermans, K; Lordick, F; Schuhmacher, C; Swallow, C; Darling, G; Wong, R; , 
2015 
Yes 
BMC Cancer
ISSN: 1471-2407
EISSN: 14712407 
BIOMED CENTRAL LTD 
LONDON 
English 
26194186 
WOS:000358113400003 
The optimal management of patients with resectable gastric cancer continues to evolve in Western countries. Following publication of the US Intergroup 0116 and UK Medical Research Council MAGIC trials, there are now two standards of care for adjuvant therapy in resectable gastric cancer, at least in the Western world: postoperative chemoradiotherapy and perioperative epirubicin/cisplatin/fluorouracil (ECF) chemotherapy. We hypothesize that adding chemoradiation to standard perioperative ECF chemotherapy will achieve further survival gains. We also believe there are advantages to administering chemoradiation in the preoperative rather than postoperative setting. In this article, we describe the TOPGEAR trial, which is a randomised phase III trial comparing control arm therapy of perioperative ECF chemotherapy with experimental arm therapy of preoperative chemoradiation plus perioperative ECF chemotherapy.